“If the US government is going to accept pharmaceutical companies’ statement that India and
other countries’ policies are not needed to ensure access to medicines, and that the companies’
assistance programs fully provide the drugs needed by their populations, then the government
should have full data on these programs. If the US government wants to accept that donation
programs solve all the access problems in developing countries, then it needs to know the actual
number of patients that need the drugs and are then able to have access to it. This information
needs to be available in order for them to make informed and accurate decisions.”
Cassedy, Claire; Reply Comments of Claire Cassedy , regarding drug company patient assistance programs, USTR docket # USTR20130040, Special 301. March, 2014.